Company: CMND
Filing Date: 2025-03-13
Form Type: POS AM
Source: 0001213900-25-023708
Chunk: 13

Company: Clearmind Medicine Inc.
Filing Date: 2025-03-13
Form: POS AM
Chunk 13
---
 common shares. |
| Nasdaq Capital Market symbol                                                                                  |     | “CMND”                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Frankfurt Stock Exchange symbol                                                                               |     | “CWY”                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

Unless otherwise stated, all information in this prospectus is based on 5,134,786 common shares outstanding as of March 12, 2025, and does not include the following as of that date:

| ● | 2,238,848 common shares issuable upon the exercise                                                                                 
 of warrants outstanding as of such date, at exercise prices ranging from $1.0777 to $243.75, all of which were vested as of such   
 date;                                                                                                                              |
| ● | 5,521 common shares issuable upon the exercise of                                                                                  
 options to directors, employees and consultants under our incentive option plan outstanding as of such date, at a weighted average 
 exercise price of $415.44, of which 5,500 were vested as of such date; and                                                         |
| ● | 1,251 common shares issuable upon the exercise of                                                                                  
 restricted share units issued to consultants under consulting agreements.                                                          |

Unless otherwise indicated, all information in this prospectus assumes or gives effect to no exercise of the warrants or options described above See “Description of Share Capital” for additional information.

<div align='center'>4

RISK FACTORS</div>

You should carefully consider the risks described below and the risks described in our 2024 Annual Report which are incorporated by reference herein, as well as the financial or other information included in this prospectus or incorporated by reference in this prospectus, including our consolidated financial statements and the related notes, before you decide to buy our securities. The risks and uncertainties described below are not the only risks facing us. We may face additional risks and uncertainties not currently known to us or that we currently deem to be immaterial. Any of the risks described below, and any such additional risks, could materially adversely affect our business, financial condition or results of operations. In such case, you may lose all or part of your original investment.

The sale of a substantial amount of our ordinary shares, including resale of the ordinary shares issuable upon the exercise of the warrants held by the selling shareholders in the public market could adversely affect the prevailing market price of our ordinary shares.

We are registering for resale an aggregate
of 1,126,480 common shares issuable upon the exercise of warrants held by the selling shareholders. Sales of substantial amounts of our
common